Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMAZE 3 trial of once-weekly subcutaneous NNC0487-0111 in overweight or obese adults with obstructive sleep apnea not receiving positive airway pressure therapy
CTR20262513Phase 3Active
- Sponsor
- Novo Nordisk
- Start
- Aug 2026
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of amycretin in obesity, Overweight, obstructive sleep apnea hypopnea syndrome (OSAHS), sponsored by Novo Nordisk. Started Aug 2026; status: active.
02
Drugs
amycretin
03
Conditions
obesityOverweightobstructive sleep apnea hypopnea syndrome (OSAHS)
Beyond the preview
Go deeper on CTR20262513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262513.